Compare MYO & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | NRSN |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.2M | 26.4M |
| IPO Year | 2017 | 2021 |
| Metric | MYO | NRSN |
|---|---|---|
| Price | $1.01 | $0.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.67 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 830.5K | 495.3K |
| Earning Date | 11-10-2025 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,643,203.00 | N/A |
| Revenue This Year | $24.07 | N/A |
| Revenue Next Year | $17.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 65.00 | N/A |
| 52 Week Low | $0.71 | $0.81 |
| 52 Week High | $7.17 | $2.60 |
| Indicator | MYO | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 34.59 |
| Support Level | $1.02 | $0.86 |
| Resistance Level | $1.13 | $1.24 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 59.77 | 3.93 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.